Condition: Unresectable Biliary Tract Cancer · Dynamic Prediction Model · Immunotherapy · Sponsor: Zhongda Hospital
This study focused on the longitudinal tumor burden profile (tumor macro features, histopathological types and imaging features, etc.), liver function, health status, tumor biomarkers, and serological indicators of patients with unresectable biliary malignancies before chemotherapy combined with immunotherapy to build a dynamic prediction model. Based on this model, risk stratification of BTC patients was realized to explore which specific populations could safely initiate combination therapy. By constructing a risk stratification model, it can help clinicians to screen the best treatment population and provide a basis for safe treatment of high-risk patients.
This description comes directly from the study's public registry record.
Gao-Jun Teng, M.D · +86-02583272121 · gjteng@vip.sina.com
Always discuss trial participation with your own doctor first.
| Zhongda Hospital, | Nanjing, Jiangsu, China | Recruiting |
| Zhongda Hospital | Nanjing, Jiangsu, China | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06849193